Tap to React
Tap to React

Scientific Committee

LIANG Tingbo

First Affiliated Hospital, Zhejiang University School of Medicine

Ulrike Harjes

Nature Medicine


Alexandra Flemming

Nature Reviews Immunology


Joao Monteiro

Nature Medicine


Peter Kirkpatrick

Nature Reviews Drug Discovery

Ioanna Pavlaki
Nature Cancer  
   

Organizer

The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU)

The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU) was founded in 1947. Over the past 79 years, it has grown into an internationally renowned medical center integrating clinical care, medical education, and scientific research. Today, FAHZU ranks among the top 1% of hospitals in China and employs more than 13,000 faculty and staff members, with 5,000 licensed beds.

As one of China’s leading tertiary hospitals, FAHZU consists of multiple centers with excellence, such as organ transplantation, pancreatic diseases, infectious diseases, hematology, nephrology, urology, and clinical pharmacy. The organ transplantation center, for instance, covers the replacement of pancreas, liver, kidney, heart, lung, and small bowel transplantation. Since the establishment of its kidney and liver transplant programs in 1977 and 1993, respectively, the center has completed more than 9,700 kidney transplants and over 5,100 liver transplants. It also leads the world in the cumulative number of living-related small bowel transplantations (LR-SBTx).

FAHZU emphasizes medical education and research. The hospital provides comprehensive medical education and professional training, including undergraduate and postgraduate education, standardized residency training, fellowship training, and continuing medical education. Many doctors trained in FAHZU have become leaders across China. FAHZU physicians and scientists have conducted outstanding medical research and competed successfully for funding from the National Natural Science Foundation of China, National Science and Technology Major Projects, and National Key R&D Programs, with annual research funding exceeding RMB 300 million for the last six consecutive years. Besides, over 800 papers have been published in prestigious journals, including Nature, Cell, Science, NEJM, and The Lancet.

FAHZU has established partnerships with over 60 leading universities and medical institutions worldwide. Multiple exchange programs are also in place. It is home to the China-Arab States Science and Technology Cooperation Center for Public Health established under the Ministry of Science and Technology of China and the Joint International Research Lab of Pancreatic Diseases entitled by the Ministry of Education of China.

As a national pioneer in digital healthcare, FAHZU is advancing the digital transformation of hospital management and clinical care through big data and artificial intelligence. The hospital has developed several internationally pioneering AI innovations, including the world’s first non-contrast CT-based AI model for early pancreatic cancer detection, a large language model and clinical decision support system for critical care medicine, an AI-assisted precision neuromodulation platform for bipolar disorder, a real-time interactive AI pathology diagnostic model, and an AI-powered non-contrast CT model for emergency diagnosis of acute aortic diseases.

Committed to excellence in healthcare, education, research, and innovation, FAHZU continues to advance its vision of becoming a world-class medical center.

.

Nature Medicine

Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine on the basis of its originality, timeliness, interdisciplinary interest and impact on improving human health. Nature Medicine also publishes commissioned content, including News, Reviews and Perspectives, aimed at contextualizing the latest advances in translational and clinical research to reach a wide audience of M.D. and Ph.D. readers. All editorial decisions are made by a team of full-time professional editors.

Nature Cancer

Nature Cancer aims to provide a unique forum through which the cancer community will learn about the latest, most significant cancer-related advances across the life, physical, applied and social sciences. Areas of interest include fundamental, preclinical research that furthers our understanding of the mechanisms underlying tumour initiation, propagation and progression; work aiming to translate this knowledge to the clinic by focusing on new approaches for the development and delivery of diagnostic and therapeutic modalities; clinical studies informing cancer diagnosis, treatment and prevention; and new ways of understanding the global societal impact of cancer. In addition to publishing original research, Nature Cancer will publish Comments, Reviews, News & Views, Features and Correspondence of high significance across the range of disciplines relating to cancer research.

Nature Reviews Immunology

Nature Reviews Immunology provides in-depth coverage of all areas of immunology, from fundamental mechanisms to applied aspects. In addition to our review articles, we highlight recent developments and exciting new primary papers in the field, as well as reflecting on the people, papers and events that have influenced the development of immunology.

Nature Reviews Immunology is part of the Nature Reviews portfolio of journals. To learn more about Nature Reviews, check out this animation and the Nature Reviews page. You can also find a summary of the editorial input and checks here.

Nature Reviews Drug Discovery
Nature Reviews Drug Discovery

Nature Reviews Drug Discovery is a monthly journal aimed at everyone working in the drug discovery and development arena. In addition to the highest-quality reviews and perspectives covering a broad scope, each issue includes news stories that investigate the hottest topics in drug discovery, timely summaries of key primary research papers, and concise updates on the latest advances in areas such as new drug approvals, patent law and emerging industry trends and strategies.